Sign in →

Test Code HSCRP C-Reactive Protein, High Sensitivity, Serum

Reporting Name

C-Reactive Protein, High Sens, S

Useful For

Assessment of risk of developing myocardial infarction in patients presenting with acute coronary syndromes

 

Assessment of risk of developing cardiovascular disease or ischemic events in individuals who do not manifest disease at present

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Serum


Advisory Information


This assay should be used to assess risk of cardiovascular disease or events.

 

CRP / C-Reactive Protein (CRP), Serum should be used to monitor or assess other inflammatory disorders.



Specimen Required


Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL


Specimen Minimum Volume

0.2 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 7 days
  Frozen  30 days

Reference Values

Lower risk: <2.0 mg/L

Higher risk: ≥2.0 mg/L

Acute inflammation: >10.0 mg/L

Day(s) and Time(s) Performed

Monday through Saturday; Continuously

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86141

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HSCRP C-Reactive Protein, High Sens, S 30522-7

 

Result ID Test Result Name Result LOINC Value
HSCRP C-Reactive Protein, High Sens, S 30522-7

Clinical Information

C-reactive protein (CRP) is a biomarker of inflammation. Plasma CRP concentrations increase rapidly and dramatically (100-fold or more) in response to tissue injury or inflammation. High-sensitivity CRP (hs-CRP) is more precise than standard CRP when measuring baseline (ie, normal) concentrations and enables a measure of chronic inflammation.

 

Atherosclerosis is an inflammatory disease and hs-CRP has been endorsed by multiple guidelines as a biomarker of atherosclerotic cardiovascular disease risk.(1-3)

 

A large prospective clinical trial demonstrated significantly less cardiovascular risk for patients with hs-CRP less than 2.0 mg/L.(1) More aggressive treatment strategies may be warranted in patients with hs-CRP of 2.0 mg/L or higher.

Interpretation

Values greater than 2.0 mg/L suggest an increased likelihood of developing cardiovascular disease or ischemic events.

Clinical Reference

1. European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, et al: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818

2. Goff DC, Lloyd-Jones DM, Bennett G, et al: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation 2014;129:S49-S73

3. Jacobson TA, Ito MK, Maki KC, et al: National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol 2014;8:473-488

Ridker PM, Danielson E, Fonseca FA, et al: Reduction in C-reactive protein and LDL-cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-1182

Analytic Time

Same day/1 day

Reject Due To

Hemolysis

Mild OK; Gross reject

Lipemia

Mild OK; Gross reject

Icterus

Mild OK; Gross reject

Other

NA

Method Name

Immunoturbidimetry

Forms

If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/cardiovascular-request-form.pdf).